A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547 Administered Subcutaneously to Healthy Subjects
Latest Information Update: 26 Sep 2022
At a glance
- Drugs ION 547 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ionis Pharmaceuticals
- 21 Sep 2022 Status changed from active, no longer recruiting to completed.
- 08 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Sep 2022.
- 08 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.